EGFR-IN-8
EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC[1].
Product Specifications
CAS Number
[2407957-87-1]
UNSPSC
12352005
Hazard Statement
H315-H319
Target
C-Met/HGFR; EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-in-8.html
Concentration
10mM
Purity
98.01
Solubility
DMSO : 8.33 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(C(F)(F)F)=C(NC(C2CC2)=O)C=C1)NC3=CC=CC(C4=NC(C5=CC=C(NC(C6=CC=CN=C6)=O)C=C5Cl)=NO4)=C3
Molecular Formula
C32H23ClF3N7O4
Molecular Weight
662.02
Precautions
P264-P280-P302+P352-P305+P351+P338-P362+P364
References & Citations
[1]Dokla EME, et al. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. Eur J Med Chem. 2019 Aug 9;182:111607.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
